Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
Deletion 6q16 syndrome is a Prader-Willi like syndrome characterized by obesity, hyperphagia, hypotonia, small hands and feet, eye/vision anomalies, and global developmental delay.
Features include very common findings: Delayed speech and language development, Global developmental delay, Obesity, and Abnormal facial shape; and common findings: Macrocephaly, Full cheeks, Narrow forehead, and Strabismus and others. 32 total HPO annotations.
Organ System | Phenotype Count | Example Features |
|---|---|---|
Brain and nerves | 6 | Delayed speech and language development, Global developmental delay, Specific learning disability |
Biomarker and diagnostic research for 6q16 deletion syndrome has been reported in the published literature.
Phenotype severity distribution: 4 very common features, 11 common features.
Estimated prevalence: <1 in 1,000,000 (VERY_RARE).
No clinical trials have been registered for 6q16 deletion syndrome.
4 publications have been identified in PubMed for 6q16 deletion syndrome. Research spans Diagnostic / Biomarker (25%), Case Report / Case Series (25%), and Clinical Trial Publication (25%).
Goh S (2026). [PMID: 41094176](https://pubmed.ncbi.nlm.nih.gov/41094176/). *Eur J Hum Genet*. [Epidemiology / Natural History]
Elsayed MEAA (2026). [PMID: 41495677](https://pubmed.ncbi.nlm.nih.gov/41495677/). *BMC Ophthalmol*. [Case Report / Case Series]
Iglesias AI (2025). [PMID: 40992929](https://pubmed.ncbi.nlm.nih.gov/40992929/). *Prenat Diagn*. [Diagnostic / Biomarker]
Duarte DDS (2024). [PMID: 39767649](https://pubmed.ncbi.nlm.nih.gov/39767649/). *Biomedicines*. [Clinical Trial Publication]
Data assembled from 4 of 12 sources · Last updated Sep 19, 2026, 9:40 PM UTC
European rare disease database
Genetic and Rare Diseases Info Center
Common questions about 6q16 deletion syndrome
Head and neck | 2 | Abnormal facial shape, Macrocephaly |
Eyes | 2 | Strabismus, Abnormality of the eye |
Arms and legs | 2 | Tapered finger, Long foot |
Muscles | 1 | Neonatal hypotonia |
Pregnancy and birth | 1 | Neonatal hypotonia |
Digestive system | 1 | Excessive hunger (polyphagia) |
AI-curated news mentioning 6q16 deletion syndrome
Updated Jul 8, 2026
A new treatment for children aged 2 or older with sickle cell disease has been approved by the U.S. Food & Drug Administration. In a press release on Wednesday, the FDA announced it had approved Casgevy, the first gene therapy for children with sickle cell disease. (NewsNation) — A new treatment for children aged 2 or older with sickle cell disease has been approved by the Food & Drug Administration (FDA). In a Wednesday news release, the FDA announced it had approved Casgevy, the first gene therapy for children with the disease. “Casgevy is a gene therapy consisting of the patient’s own (autologous) hematopoietic (blood) stem cells, administered as a one-time single dose for intravenous infusion,” the release noted. “Pediatric patients as young as 2 years of age can now access a critical additional treatment option to treat these debilitating, life-threatening diseases,” Karim Mikhail, the acting director of the Center for Biologics Evaluation and Research, wrote. “These disorders carry a heavy burden for children and their families, affecting growth, development, and long-term health in profound ways,” Megha Kaushal, acting deputy director of the Office of Therapeutic Products in CBER, said in the release.